MeSH tree: C07.550.350
Nasopharyngeal carcinoma (or NPC) is a rare type of cancer affecting the epithelial tissue of the nasopharynx, the upper part of the throat behind the nasal cavity. Among the three main subtypes of NPC, non-keratinizing undifferentiated ...
Mar 26, 2024
0
55
According to the American Journal of Roentgenology (AJR), using a 6-mm threshold, rather than a 5-mm threshold, helps facilitate better risk stratification and treatment decisions in patients with nasopharyngeal carcinoma ...
Sep 29, 2023
0
55
Research led by the Sun Yat-sen University Cancer Center in China has highlighted genetic risks for nasopharyngeal carcinoma. In a paper titled "High-throughput identification of regulatory elements and functional assays ...
Nasopharyngeal carcinoma (NPC) is a type of cancer that occurs in the nasopharynx, which is located behind the nose and above the back of the throat. NPC has a geographically skewed distribution worldwide, with high incidence ...
Jun 7, 2023
0
20
A team led by the National Cancer Centre Singapore (NCCS) with members from Singapore General Hospital, A*STAR's Institute of Molecular and Cell Biology (IMCB) and Genome Institute of Singapore (GIS), National University ...
Jun 7, 2023
0
80
In clinical applications, pathologists usually combine information of histopathological images at different magnifications, that is, from subnuclear O (0.1 μ m) to cells [≈ O (10 μ m)] and intercellular [≈ O (100 μ m)], to ...
Feb 10, 2023
0
39
Led by the Department of Clinical Oncology, School of Clinical Medicine, LKS Faculty of Medicine, the University of Hong Kong (HKUMed), an international group of the world's top clinicians in managing nasopharyngeal carcinoma ...
Feb 6, 2023
0
32
Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against COVID-19 could reduce the success of cancer treatment ...
Nov 8, 2022
0
30
The U.S. Food and Drug Administration approved Dupixent (dupilumab) as the first treatment for adults with prurigo nodularis, according to Regeneron Pharmaceuticals.
Oct 3, 2022
0
68
